SCHEMBL1741769

SCHEMBL1741769

O=C(O)CCCNCCNCCCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
TSHR P16473 3/20 0.53
NFKB1 P19838 2/20 0.53
PMP22 Q01453 1/20 0.53
PRMT1 Q99873 1/20 0.48
CAMK2A Q9UQM7 1/20 0.48
GABRR3 A8MPY1 1/20 0.46
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
HDAC3 O15379 1/20 0.46
GABBR2 O75899 1/20 0.46
CYP1A2 P05177 1/20 0.46
THRB P10828 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRR1 P24046 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRR2 P28476 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11896840 1.00 LMNA (0.56) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL2461935 0.97 LMNA (0.53) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL2468753 0.97 LMNA (0.53) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL112741 0.97 LMNA (0.59) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL14761645 0.95 PRMT1 (0.56) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL2459523 0.95 PRMT1 (0.56) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL2456770 0.95 PRMT1 (0.56) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL2462143 0.95 PRMT1 (0.56) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL14761768 0.95 PRMT1 (0.56) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL14761489 0.95 PRMT1 (0.56) LMNASLC22A6TSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130210922-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNIPHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2013-08-15 US claimed
WO-2011144335-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2011-11-24 WO claimed
EP-0804455-A4 RAPID AND SENSITIVE DETECTION OF ANTIBIOTIC-RESISTANT MYCOBACTERIA USING OLIGONUCLEOTIDE PROBES SPECIFIC FOR RIBOSOMAL RNA PRECURSORS MICROPROBE CORP (US) 2000-01-12 EP claimed
US-5726021-A PRETREATING CELLS BY ENZYME DEGRADATION, MAGNESIUM CHELATORS, NONIONIC AND ANIONIC DETERGENTS AND HEATING BECTON DICKINSON AND COMPANY (US) 1998-03-10 US claimed
EP-0804455-A1 RAPID AND SENSITIVE DETECTION OF ANTIBIOTIC-RESISTANT MYCOBACTERIA USING OLIGONUCLEOTIDE PROBES SPECIFIC FOR RIBOSOMAL RNA PRECURSORS MICROPROBE CORPORATION (US) 1997-11-05 EP claimed
WO-1995034574-A1 RAPID AND SENSITIVE DETECTION OF ANTIBIOTIC-RESISTANT MYCOBACTERIA USING OLIGONUCLEOTIDE PROBES SPECIFIC FOR RIBOSOMAL RNA PRECURSORS MICROPROBE CORPORATION (US) 1995-12-21 WO claimed
CN-107670027-B Compositions and methods for treating skin conditions ZO皮肤健康公司 2023-05-19 CN disclosed
CN-114080236-A Compositions and methods for treating biofilm-associated pulmonary conditions 轨迹IP有限责任公司 2022-02-22 CN disclosed
US-20130210922-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNIPHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2013-08-15 US disclosed
EP-2389923-B1 Stable ready to use injectable paracetamol formulation UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB S A (GR) 2013-01-30 EP disclosed
US-20110318290-A1 Compounds and Methods for Inhibiting Axillary Malodour GIVAUDAN SA (CH) 2011-12-29 US disclosed
EP-2389923-A1 Stable ready to use injectable paracetamol formulation Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) 2011-11-30 EP disclosed
WO-2011144335-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2011-11-24 WO disclosed
WO-2002092024-A2 COMPOUNDS AND METHODS FOR INHIBITING AXILLARY MALODOUR GIVAUDAN SA (CH) 2002-11-21 WO disclosed
EP-0804455-A4 RAPID AND SENSITIVE DETECTION OF ANTIBIOTIC-RESISTANT MYCOBACTERIA USING OLIGONUCLEOTIDE PROBES SPECIFIC FOR RIBOSOMAL RNA PRECURSORS MICROPROBE CORP (US) 2000-01-12 EP disclosed
US-5770373-A Rapid and sensitive detection of antibiotic-resistant mycobacteria using oligonucleotide probe specific for ribosomal RNA precursors BECTON DICKINSON AND COMPANY (US) 1998-06-23 US disclosed
US-5726021-A PRETREATING CELLS BY ENZYME DEGRADATION, MAGNESIUM CHELATORS, NONIONIC AND ANIONIC DETERGENTS AND HEATING BECTON DICKINSON AND COMPANY (US) 1998-03-10 US disclosed
US-5712095-A Rapid and sensitive detection of antibiotic-resistant mycobacteria using oligonucleotide probes specific for ribosomal RNA precursors BECTON DICKINSON AND COMPANY (US) 1998-01-27 US disclosed
EP-0804455-A1 RAPID AND SENSITIVE DETECTION OF ANTIBIOTIC-RESISTANT MYCOBACTERIA USING OLIGONUCLEOTIDE PROBES SPECIFIC FOR RIBOSOMAL RNA PRECURSORS MICROPROBE CORPORATION (US) 1997-11-05 EP disclosed
WO-1995034574-A1 RAPID AND SENSITIVE DETECTION OF ANTIBIOTIC-RESISTANT MYCOBACTERIA USING OLIGONUCLEOTIDE PROBES SPECIFIC FOR RIBOSOMAL RNA PRECURSORS MICROPROBE CORPORATION (US) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318290-A1 Compounds and Methods for Inhibiting Axillary Malodour TYR, AOX1, APEH LMNA 4807/4885SLC22A6 3410/4885TSHR 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.